Isofol Medical
Clinical-stage biotech developing a folate-based therapy to enhance cancer treatments.
ISOFOL | ST
Overview
Corporate Details
- ISIN(s):
- SE0009581051
- LEI:
- 549300MCXYAHG7VBHX75
- Country:
- Sweden
- Address:
- C/O Biotech Center, Arvid Wallgrens, 413 46 Göteborg
- Website:
- https://isofolmedical.com/
Description
Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-05-19 19:00 |
Kommuniké från årsstämma i Isofol Medical AB (publ) den 19 maj 2022
|
Swedish | 96.5 KB | ||
| 2022-05-19 19:00 |
Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on May 19…
|
English | 96.7 KB | ||
| 2022-05-12 08:00 | Swedish | 771.0 KB | |||
| 2022-05-12 08:00 | English | 784.3 KB | |||
| 2022-04-27 08:01 | Swedish | 7.9 MB | |||
| 2022-04-27 08:01 | Swedish | 7.9 MB | |||
| 2022-04-22 12:45 |
Isofol announces start of study data analysis of phase III AGENT study in advan…
|
English | 187.1 KB | ||
| 2022-04-22 12:45 |
Isofol påbörjar analysen av studiedata från fas III-studien AGENT inom metastas…
|
Swedish | 143.2 KB | ||
| 2022-04-12 10:00 |
Notice to attend the Annual General Meeting held on May 19, 2022 in Isofol Medi…
|
English | 235.5 KB | ||
| 2022-04-12 10:00 |
Kallelse till årsstämma den 19 maj 2022 i Isofol Medical AB (publ)
|
Swedish | 221.1 KB | ||
| 2022-04-08 15:30 |
Isofol Medical AB’s (publ) Nomination Committee proposes New Chair of the Board
|
English | 61.3 KB | ||
| 2022-04-08 15:30 |
Isofol Medical AB (publ) valberedning föreslår ny ordförande
|
Swedish | 60.1 KB | ||
| 2022-02-24 08:00 | Swedish | 902.5 KB | |||
| 2022-02-24 08:00 | English | 912.4 KB | |||
| 2021-12-03 20:15 |
Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with …
|
English | 74.4 KB |
Automate Your Workflow. Get a real-time feed of all Isofol Medical filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Isofol Medical
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Isofol Medical via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-11 | Magnus Hurst | Other | Buy | 35,000 | 24,150.00 SEK |
| 2022-09-12 | AB Windar | Other | Buy | 500,000 | 305,000.00 SEK |
| 2021-12-09 | Tony Gustavsson | Other | Sell | 58,767 | 858.00 SEK |
| 2021-12-09 | Tony Gustavsson | Other | Sell | 58,767 | 152.79 SEK |
| 2021-06-14 | HealthCom GmbH | Other | Buy | 233,336 | 1,493,350.40 SEK |
| 2021-06-10 | Gustaf Albèrt | Other | Other | 15,153 | 96,979.20 SEK |
| 2020-11-23 | Tony Gustavsson | Other | Buy | 58,767 | 43,487.58 SEK |
| 2020-11-23 | Tony Gustavsson | Other | Buy | 58,767 | 29,971.17 SEK |
| 2020-11-16 | Sven Eriksson | Other | Sell | 58,767 | 43,487.58 SEK |
| 2020-11-16 | Sven Eriksson | Other | Sell | 58,767 | 29,971.17 SEK |
Peer Companies
